FDA Advisers Support Approval Of New Hepatitis C Drug

SILVER SPRING, Md. (October 24, 2013)--An experimental hepatitis C drug from Johnson & Johnson has won unanimous support from a panel of government experts.

The experts say the medication should be approved to treat patients infected with the liver-destroying virus.

All 19 members of a panel of Food and Drug Administration advisers voted in favor of approving J&J's simeprevir, a daily pill designed to eliminate the most common form of hepatitis C.

The FDA is not required to follow the group's recommendation, although it often does.

A decision on the drug is expected next month.

More than 3 million people in the U.S. have hepatitis C, a blood-borne disease that causes liver damage and is blamed for 15,000 deaths a year.

J&J is one of a half-dozen companies working to develop more effective treatments for the virus.

KWTX-TV News 10 6700 American Plaza Waco, Texas 76712 (254) 776-1330 Fax (254) 751-1088
Copyright © 2002-2016 - Designed by Gray Digital Media - Powered by Clickability 229154301 - kwtx.com/a?a=229154301
Gray Television, Inc.